pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

66 catalysts · 16 phase 2 completion · 13 phase 1 completion · 8 phase 1 initiation · 7 patent expiry · 7 phase 2 initiation · 3 constraining patent expiry europe

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 0 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: hypertension×TA: infectious-disease×TA: immunology×clear all
type
  • phase 2 completion16
  • phase 1 completion13
  • phase 1 initiation8
  • patent expiry7
  • phase 2 initiation7
  • constraining patent expiry europe
3
  • drug expiry3
  • phase 3 completion3
  • phase 3 initiation2
  • phase 0 trial completion1
  • therapy area
    • Oncology127
    • Infectious Disease38
    • Cardiology36
    • Immunology28
    • Dermatology26
    • Pulmonology18
    • Women's Health15
    • Ophthalmology14
    • Pain11

    Week of Apr 20, 2026

    5
    ›Apr 26, 2026phase 2 completion90d agoUniversity Health Network — decidual stromal cells (Phase II Trial Completion)decidual stromal cells

    Therapy area: Immunology. Indication: Graft Versus Host Disease (GVHD)

    full page →decidual stromal cells →source: globaldata
    ›Apr 26, 2026phase 2 completion90d agoBangalore Medical College and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Infectious Disease, Women's Health. Indication: Labor And Delivery, Pregnancy, Puerperal Infection

    full page →bupivacaine →source: globaldata
    ›Apr 26, 2026phase 2 initiation90d agoTianFang Pharmaceutical Co — diclofenac sodium DR (Phase II Trial Initiation)DICLOFENAC SODIUM

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Dental Pain (Toothache/Tooth Pain), Dysmenorrhea, Gouty Arthritis (Gout), Injury, Myalgia (Muscle Pain), Osteoarthritis, Pain, Post-Operative Pain, Rheumatic Disorders, Rheumatoid Arthritis, Spondyloarthritis (Spondyloarthropathy), Tenosynovitis

    full page →DICLOFENAC SODIUM →source: globaldata
    ›Apr 26, 2026phase 3 completion90d agoHubei Provincial Center for Disease Control and Prevention — rabies vaccine (Phase III Trial Completion)rabies vaccine

    Therapy area: Infectious Disease. Indication: Rabies

    full page →rabies vaccine →source: globaldata
    ›Apr 26, 2026phase 3 initiation90d agoStanford University — zanubrutinib (Phase III Trial Initiation)zanubrutinib

    Therapy area: Immunology. Indication: Immunoglobulin G4-Related Disease (IgG4-RD)

    full page →zanubrutinib →source: globaldata

    Week of Apr 27, 2026

    45
    ›Apr 27, 2026phase 1 initiation89d agoNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)pembrolizumab

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)

    full page →pembrolizumab →source: globaldata
    ›Apr 27, 2026constraining patent expiry europe
    ← prev
    page 1 of 2
    next →
    89d ago
    Bill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Europe))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026patent expiry89d agoBill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Japan))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026phase 1 completion89d agoCTI Clinical Trial and Consulting Services Australia Pty Ltd — PTC-844 (Phase I Trial Completion)PTC-844

    Therapy area: Immunology. Indication: Unspecified Immunological Disorders

    full page →PTC-844 →source: globaldata
    ›Apr 27, 2026phase 1 completion89d agoFortrea Holdings Inc — balinatunfib (Phase I Trial Completion)balinatunfib

    Therapy area: Gastrointestinal, Immunology. Indication: Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Ulcerative Colitis

    full page →balinatunfib →source: globaldata
    ›Apr 27, 2026phase 1 initiation89d agoNational Heart Lung and Blood Institute — fostamatinib (Phase I Trial Initiation)fostamatinib

    Therapy area: Immunology. Indication: Liver Transplant Rejection

    full page →fostamatinib →source: globaldata
    ›Apr 27, 2026phase 2 completion89d agoEuropean and Developing Countries Clinical Trials Partnership — (diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine (Phase II Trial Completion)(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine

    Therapy area: Infectious Disease. Indication: Salmonella Infections

    full page →(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoNational Institute of Neurological Disorders and Stroke — brincidofovir (Phase II Trial Initiation)brincidofovir

    Therapy area: Infectious Disease. Indication: Progressive Multifocal Leukoencephalopathy

    full page →brincidofovir →source: globaldata
    ›Apr 27, 2026phase 3 completion89d agoSanofi — meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) (Phase III Trial Completion)meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi)

    Therapy area: Infectious Disease. Indication: Neisseria meningitidis Infections

    full page →meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) →source: globaldata
    ›Apr 27, 2026phase 3 initiation89d agoUniversity of Thessaly — abatacept (Phase III Trial Initiation)abatacept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →abatacept →source: globaldata
    ›Apr 27, 2026phase iv trial initiation89d agoAll India Institute of Medical Sciences Patna — typhoid Vi polysaccharide vaccine (Phase IV Trial Initiation)typhoid Vi polysaccharide vaccine

    Therapy area: Infectious Disease. Indication: Typhoid Fever

    full page →typhoid Vi polysaccharide vaccine →source: globaldata
    ›Apr 28, 2026constraining patent expiry europe88d agoLupin Ltd — (dolutegravir + lamivudine + tenofovir disoproxil fumarate) (Constraining Patent Expiry (Europe))(dolutegravir + lamivudine + tenofovir disoproxil fumarate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(dolutegravir + lamivudine + tenofovir disoproxil fumarate) →source: globaldata
    ›Apr 28, 2026patent expiry88d agoGSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →dolutegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry88d agoGSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))(abacavir sulfate + dolutegravir sodium + lamivudine)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(abacavir sulfate + dolutegravir sodium + lamivudine) →source: globaldata
    ›Apr 28, 2026patent expiry88d agoGSK plc — cabotegravir sodium (Constraining Patent Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry88d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Constraining Patent Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026patent expiry88d agoViiV Healthcare UK Ltd — cabotegravir LA (Constraining Patent Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry88d agoGSK plc — cabotegravir sodium (Drug Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026drug expiry88d agoViiV Healthcare UK Ltd — cabotegravir LA (Drug Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry88d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Drug Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026pdufa88d agoMerck & Co Inc — (doravirine + islatravir hydrate) (PDUFA)(doravirine + islatravir hydrate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(doravirine + islatravir hydrate) →source: globaldata
    ›Apr 28, 2026phase 1 completion88d agoGSK plc — bepirovirsen sodium (Phase I Trial Completion)bepirovirsen sodium

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →bepirovirsen sodium →source: globaldata
    ›Apr 28, 2026phase 1 completion88d agoBio-Innova Co Ltd — clarithromycin (Phase I Trial Completion)clarithromycin

    Therapy area: Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System, Infectious Disease, Mouth and Dental Disorders, Respiratory. Indication: Abscess, Acne Vulgaris, Acute Bacterial Sinusitis, Acute Bronchitis, Acute Pharyngitis, Bacterial Pneumonia, Bacterial Respiratory Tract Infections, Bartonella Infections, Bronchitis, Carbuncle, Cellulitis, Chlamydia trachomatis Pneumonia, Chronic Bronchitis, Community Acquired Pneumonia, Community-Acquired

    full page →clarithromycin →source: globaldata
    ›Apr 28, 2026phase 1 initiation88d agoShanghai Argo Pharmaceutical Co Ltd — BW-20805 (Phase I Trial Initiation)BW-20805

    Therapy area: Immunology. Indication: Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

    full page →BW-20805 →source: globaldata
    ›Apr 28, 2026phase 1 initiation88d agoShenzhen MagicRNA Biotech Co Ltd — HN-2302 (Phase I Trial Initiation)HN-2302

    Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)

    full page →HN-2302 →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoInonu University — albumin gel- and platelet- rich fibrin (Phase II Trial Completion)albumin gel- and platelet- rich fibrin

    Therapy area: Immunology, Mouth and Dental Disorders. Indication: Inflammation, Periodontal Disease, Periodontitis

    full page →albumin gel- and platelet- rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 initiation88d agoTianjin Lisheng Pharmaceutical Co Ltd — dexamethasone acetate (Phase II Trial Initiation)dexamethasone acetate

    Therapy area: Immunology, Respiratory. Indication: Allergic Rhinitis, Inflammation, Transplant Rejection

    full page →dexamethasone acetate →source: globaldata
    ›Apr 28, 2026phase 3 completion88d agoGovernment Stanley Medical College Hospital — tenecteplase (Phase III Trial Completion)tenecteplase

    Therapy area: Genito Urinary System, Infectious Disease. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Unspecified Bacterial Infections

    full page →tenecteplase →source: globaldata
    ›Apr 29, 2026phase 1 initiation87d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

    full page →adenovirus vector (spike protein) vaccine →source: globaldata
    ›Apr 29, 2026phase 2 completion87d agoSaraswati Dhanwantari Dental College and Hospital Parbhani — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

    Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Periodontitis, Unspecified Infectious Diseases

    full page →(amoxicillin + clavulanic acid) →source: globaldata
    ›Apr 29, 2026phase 2 initiation87d agoNefro Avillion Clinical Development LLC — siplizumab (Phase II Trial Initiation)siplizumab

    Therapy area: Immunology. Indication: Kidney Transplant Rejection

    full page →siplizumab →source: globaldata
    ›Apr 29, 2026phase 2 initiation87d agoKyowa Kirin Co Ltd — KK-4277 (Phase II Trial Initiation)KK-4277

    Therapy area: Immunology. Indication: Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus

    full page →KK-4277 →source: globaldata
    ›Apr 29, 2026phase 2 initiation87d agoYunpeng Pharmaceutical Co Ltd — norfloxacin (Phase II Trial Initiation)norfloxacin

    Therapy area: Gastrointestinal, Genito Urinary System, Infectious Disease. Indication: Gonorrhea, Intestinal Infection, Salmonella Infections, Typhoid Fever, Urinary Tract Infections

    full page →norfloxacin →source: globaldata
    ›Apr 29, 2026phase 2 initiation87d agoHuahui Health Ltd — HH-006 (Phase II Trial Initiation)HH-006

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →HH-006 →source: globaldata
    ›Apr 30, 2026constraining patent expiry europe86d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026patent expiry86d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

    Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

    full page →isavuconazonium sulfate →source: globaldata
    ›Apr 30, 2026phase 0 trial completion86d agoUniversity of Southern California — methylprednisolone (Phase 0 Trial Completion)MEDROL

    Therapy area: Immunology. Indication: Drug Hypersensitivity Reactions

    full page →MEDROL →source: globaldata
    ›Apr 30, 2026phase 1 completion86d agoDongguan Traditional Chinese Medicine Hospital — undisclosed traditional Chinese medicine (Phase I Trial Completion)undisclosed traditional Chinese medicine

    Therapy area: Immunology, Musculoskeletal Disorders. Indication: Osteoporosis, Rheumatoid Arthritis, Sarcopenia

    full page →undisclosed traditional Chinese medicine →source: globaldata
    ›Apr 30, 2026phase 1 completion86d agoShenzhen Digestive System Disease Clinical Medicine Research Center — tegoprazan (Phase I Trial Completion)tegoprazan

    Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

    full page →tegoprazan →source: globaldata
    ›Apr 30, 2026phase 1 completion86d agoCheng Du Sheng Nuo Biotec Co Ltd — CIGB-814 (Phase I Trial Completion)CIGB-814

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →CIGB-814 →source: globaldata
    ›Apr 30, 2026phase 1 completion86d agoEcolab Inc — (acetaminophen + ibuprofen) (Phase I Trial Completion)(acetaminophen + ibuprofen)

    Therapy area: Central Nervous System, Ear Nose Throat Disorders, Hormonal Disorders, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Ankylosing Spondylitis (Bekhterev's Disease), Dental Pain (Toothache/Tooth Pain), Fever, Fibromyalgia (Fibromyalgia Syndrome), Gouty Arthritis (Gout), Hyperthyroidism, Laryngitis, Low Back Pain, Mixed Pain (Nociceptive Pain/Neuropathic Pain), Musculoskeletal Inflammation, Musculoskeletal Pain, Myalgia (Muscle Pain), Neuropathic Pa

    full page →(acetaminophen + ibuprofen) →source: globaldata
    ›Apr 30, 2026phase 1 completion86d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

    Therapy area: Immunology. Indication: Inflammation

    full page →FT-2109 →source: globaldata
    ›Apr 30, 2026phase 1 completion86d agoMAXVAX Biotechnology Co Ltd — MKK-900 (Phase I Trial Completion)MKK-900

    Therapy area: Infectious Disease. Indication: Respiratory Syncytial Virus (RSV) Infections

    full page →MKK-900 →source: globaldata
    ›Apr 30, 2026phase 1 completion86d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

    Therapy area: Immunology. Indication: Inflammation

    full page →FT-2109 →source: globaldata
    ›Apr 30, 2026phase 1 completion86d agoJohns Hopkins University — ciprofloxacin (Phase I Trial Completion)ciprofloxacin

    Therapy area: Infectious Disease. Indication: Bacillary Dysentery (Shigellosis)

    full page →ciprofloxacin →source: globaldata
    $GSK51.35+1.20%
    $FTRE19.52+0.10%
    $SNY43.35-0.02%
    $GSK51.35+1.20%
    $GSK51.35+1.20%
    $GSK51.35+1.20%
    $MRK131.07+0.45%
    $OCGN1.2100-4.72%
    $GSK51.35+1.20%
    $CPIX6.6100-5.37%
    $ECL268.75+2.13%